Neuropathic pain (NP) is a prominent form of pain associated with a wide variety of common diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, stroke, and multiple sclerosis. The NP market is one of moderate commercial opportunity, with a more favorable outlook for developers of drugs with novel mechanisms of action. The current and forthcoming availability of multiple generic first-line analgesics as well as the entrenchment of available treatment options in current medical practice presents notable barriers to market penetration of new drugs. Nevertheless, interviewed thought leaders tell us that many NP patients do not adequately respond to current treatment. Furthermore, unmet need for novel analgesics continues to be driven by the growing prevalence of the NP patient population and the significant percentage of patients refractory to or unable to tolerate current treatment options.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 31 country-specific interviews with thought leaders, neuropathic pain experts, pain specialists, and neurologists.
Epidemiology: Prevalence of neuropathic back pain, painful diabetic neuropathy, neuropathic cancer pain, and HIV/AIDS-related NP in the major pharmaceutical markets under study. Diagnosed prevalence of postherpetic neuralgia in the major pharmaceutical markets under study. Other types of NP, including trigeminal neuralgia, central NP, postoperative NP, carpal tunnel syndrome, and complex regional pain syndrome, were also part of our research.
Emerging therapies: Phase II: 36 drugs; Phase II/III and Phase III: 6 drugs; coverage of 34 select preclinical and Phase I products.
Market forecast features: We present market segmentation of select NP populations in the base year of our forecast (2012); we provide an in-depth examination of current and future NP drug-treatment trends and market performance over a ten-year forecast period (2012-2022) and forecast major-market NP drug sales, by country for key therapies for the treatment of NP through 2022.